Stock Research: Pacific Biosciences of California

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Pacific Biosciences of California

NasdaqGS:PACB US69404D1081
16
  • Value
    27
  • Growth
    65
  • Safety
    Safety
    21
  • Combined
    16
  • Sentiment
    27
  • 360° View
    360° View
    16
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures advanced sequencing solutions. The company operates in the life science technology industry. In the last fiscal year, the company had a market cap of $441 million, profits of $38 million, revenue of $154 million, and 575 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 16 (better than 16% compared with alternatives), overall professional sentiment and financial characteristics for the stock Pacific Biosciences of California are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Pacific Biosciences of California. The consolidated Growth Rank has a good rank of 65, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 65% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 21 means that the share price of Pacific Biosciences of California is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 79% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 27, which means that the company has a riskier financing structure than 73% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 27, indicating professional investors are more pessimistic about the stock than for 73% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
21 73 14 21
Growth
65 45 93 35
Safety
Safety
27 37 15 87
Sentiment
27 9 26 33
360° View
360° View
16 21 10 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
42 32 44 20
Opinions Change
50 15 57 50
Pro Holdings
n/a 36 25 73
Market Pulse
26 14 52 46
Sentiment
27 9 26 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
21 73 14 21
Growth
65 45 93 35
Safety Safety
27 37 15 87
Combined
16 53 21 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
40 40 40 8
Price vs. Earnings (P/E)
68 68 5 13
Price vs. Book (P/B)
1 76 40 54
Dividend Yield
1 1 1 1
Value
21 73 14 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
78 96 94 91
Profit Growth
8 6 60 1
Capital Growth
97 83 84 87
Stock Returns
35 13 69 13
Growth
65 45 93 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
10 13 8 100
Refinancing
91 92 57 89
Liquidity
13 17 28 4
Safety Safety
27 37 15 87

Similar Stocks

Discover high‑ranked alternatives to Pacific Biosciences of California and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.